Mechanisms of Action and Clinical Development of Elotuzumab - Ritchie - 2018 - Clinical and Translational Science - Wiley Online Library
BMS and AbbVie's myeloma drug Empliciti gains approval -
FDA Approves EMPLICITI® Combination for Relapsed Refractory Multiple Myeloma – OncoPrescribe
Empliciti (elotuzumab) for the Treatment of Multiple Myeloma, USA
POMALYST® (pomalidomide) Mechanism of Action
![Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]](https://www.thno.org/v11/p3580/toc.jpg "Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]")
Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma | SpringerLink
Mechanism of action of anti-CS1 antibody (elotuzumab) against multiple... | Download Scientific Diagram
Bristol Myers Squibb - Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
FDA Approves Empliciti Combination for Relapsed or Refractory… – Myeloma Research News
First and only antibody for Multiple Myeloma approved in EU
Mechanism of Action | EMPLICITI® (elotuzumab)
Mechanism of Action | EMPLICITI® (elotuzumab)
Efficacy Data | POMALYST® (pomalidomide) + dex + EMPLICITI® (elotuzumab)
NDC 0003-4522 Empliciti Elotuzumab
Mechanism of Action | EMPLICITI® (elotuzumab)
Elotuzumab (Empliciti) Drug Info
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma | Oncology Practice Management
Second Multiple Myeloma Antibody Approved – Empliciti | Cancer Biology
Second Multiple Myeloma Antibody Approved – Empliciti | Cancer Biology
Elotuzumab: Uses, Interactions, Mechanism of Action | DrugBank Online
Precision Medicine Empliciti Improves Survival of Recurrent Multiple Myeloma - CancerConnect
